🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being described as a "significant breakthrough" in the battle against increasingly resistant strains of the infection, according to health experts.

A Worldwide Challenge

Gonorrhoea infections are escalating worldwide, with figures suggesting in excess of 82 million instances each year. Especially elevated rates are seen in the African continent and countries within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of new treatments for gonorrhoea is an important and timely step in the context of increasing worldwide cases, the spread of superbugs and the extremely scarce available drugs presently on offer.”

Medical experts are increasingly worried about the surge in antibiotic-resistant strains. The global health body has listed it as a "critical concern". Ongoing monitoring showed that the effectiveness of standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Drugs Gain Clearance

Zoliflodacin, alternatively called Nuzolvence, was cleared by the US Food and Drug Administration in mid-December for use against gonorrhoea. This STI can lead to significant complications, including infertility. Scientists believe that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, developed by the pharmaceutical company GSK, also received approval in the same week. This treatment, which is employed against urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a innovative non-profit model for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to bring it to fruition.

“This approval marks a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which previously has been staying ahead of antibiotic development.”

Testing Outcomes and Worldwide Availability

According to data released by a prominent scientific publication, zoliflodacin cured over nine in ten of cases of the STI. This places it at an similar efficacy with the existing first-line therapy, which uses a dual-drug approach. The study involved hundreds of participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the ability to make available and distribute the drug in a wide range of low-income and middle-income countries.

Doctors treating patients have shared optimism. Having a one-pill regimen such as this is seen as a "game-changer" for managing the epidemic. This is viewed as crucial to alleviate the strain of the illness for individuals and to halt the transmission of untreatable gonorrhoea globally.